Sanofi

Sanofi Debt

The Debt of Sanofi (SAN.PA) as of Nov 16, 2026 is 20.33 B EUR. In the previous year, Debt was 17.91 B EUR — a change of 13.53% (higher).

Debt

20.33 BEUR

YoY

13.53%

Last updated:

In 2025, Sanofi's total debt was 20.33 B EUR, a 13.53% change from the 17.91 B EUR total debt recorded in the previous year.

The Sanofi Debt history

  • 3 Years

  • 10 Years

  • 25 Years

  • Max

Debt
Date
Debt
Jan 1, 2018
24.64 B EUR
Jan 1, 2019
25.93 B EUR
Jan 1, 2020
23.72 B EUR
Jan 1, 2021
22.47 B EUR
Jan 1, 2022
21.50 B EUR
Jan 1, 2023
18.42 B EUR
Jan 1, 2024
17.91 B EUR
Jan 1, 2025
20.33 B EUR
The Sanofi Debt history
YEARDebtYoY
20.33 BEUR+13.53%
17.91 BEUR-2.80%
18.42 BEUR-14.31%
21.50 BEUR-4.31%
22.47 BEUR-5.30%
23.72 BEUR-8.52%
25.93 BEUR+5.25%
24.64 BEUR+57.94%
15.60 BEUR-16.03%
18.58 BEUR+12.23%
16.55 BEUR+11.75%
14.81 BEUR—

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Sanofi Stock analysis

What does Sanofi do? Sanofi SA is a French company that was formed in 1973 from a merger of two French pharmaceutical and biotechnology companies. It is one of the largest players in the healthcare industry worldwide and employs over 100,000 employees. The objective of Sanofi is to improve people's lives through innovative medicines and therapies. In this regard, the company pursues a comprehensive business model that focuses on both research and development, as well as the production and distribution of medications and vaccines. The company has different divisions and product lines, which are divided into three business areas: Innovative Medicine, Consumer Healthcare, and Generic Pharmaceuticals. Innovative Medicine utilizes state-of-the-art technologies and scientific knowledge to treat the most challenging diseases. In the area of Consumer Healthcare, the company offers a wide range of over-the-counter products such as vitamins, dietary supplements, cough and cold remedies, as well as oral and dental health products. In the Generic Pharmaceuticals field, the company produces more cost-effective alternatives to expensive brand-name products, providing a variety of generic medications. Sanofi is a leading manufacturer of medications that are of great significance in various areas such as diabetes, oncology, cardiovascular diseases, and neurology. In recent years, the company has also established a strong presence in the field of vaccines. Here, Sanofi develops and produces innovative vaccines against COVID-19, influenza, and other infectious diseases. Sanofi is present in more than 170 countries and collaborates closely with physicians, research institutions, and health authorities to improve healthcare worldwide. The company conducts research and development in various disciplines and invests a significant amount each year in the development of innovative medicines and therapies. Overall, Sanofi SA is an emerging company in the pharmaceutical and healthcare sector. The portfolio of products and therapies offered by Sanofi is extensive and covers many areas of healthcare. Sanofi relies on continuous innovation and continuously works to improve healthcare and enhance the lives of people worldwide. Sanofi is one of the most popular companies on Eulerpool.

Debt Details

Understanding Sanofi's Debt Structure

Sanofi's total debt refers to the cumulative financial obligations the company owes to external parties. This can include short-term and long-term borrowings, bonds, loans, and other financial instruments. Assessing the company's debt levels is crucial for evaluating its financial health, risk profile, and ability to fund operations and expansions.

Year-to-Year Comparison

Analyzing Sanofi's debt structure over the years provides insights into the firm’s financial strategy and stability. A reduction in debt can indicate financial strength and operational efficiency, while an increase may signal growth investments or potential financial challenges ahead.

Impact on Investments

Investors pay close attention to Sanofi’s debt levels as they can influence the company’s risk and return profiles. Excessive debt can lead to financial strain, while moderate and well-managed debt can be a catalyst for growth and expansion, making it a critical aspect of investment evaluations.

Interpreting Debt Fluctuations

Shifts in Sanofi’s debt levels can be attributed to various operational and strategic factors. An increase in debt might be geared towards funding expansion projects or enhancing operational capacity, while a decrease may indicate profit realizations or an approach to minimize financial risk and leverage.

Frequently Asked Questions about Sanofi stock

Debt of Sanofi is 20.33 B EUR in 2025.

Debt of Sanofi changed from 17.91 B EUR to 20.33 B EUR, representing a 13.53% change. The value is higher than the previous year.

On Eulerpool you can find the complete historical development of Debt Sanofi since 2006 – with annual values, charts, and detailed analysis.

Debt's EUR is a key factor for investors. Changes in this metric can signal improving or deteriorating fundamentals, directly impacting the stock price. On Eulerpool, you can track Debt's Sanofi historically and in real time.

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Balance Sheet — Sanofi

All Key Metrics — Sanofi